PGAP3 Gene Analysis – Hyperphosphatasia with Intellectual Disability Syndrome Type 4 (HPMRS4) Genetic Test in UAE | 2,800 AED | 2026 DHA Guidelines

تحليل جين PGAP3 لفرط الفوسفاتاز مع متلازمة الإعاقة الذهنية من النوع الرابع (HPMRS4) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي

Executive Summary | الملخص التنفيذي

99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited NGS sequencing. Secure, VIP home-based sample collection (8 am–11 pm) with cold‑chain transport. Tele‑guidance by DHA‑licensed clinicians post‑result. Direct insurance billing verification through WhatsApp at +971 54 548 8731.

حساسية تشخيصية 99.9% عبر تسلسل الجيل التالي المعتمد ISO 9001:2015. خدمة جمع العينات المنزلية الفاخرة (8 صباحاً – 11 مساءً) مع سلسلة تبريد متكاملة. استشارة سريرية بعد التحليل مع أطباء مرخصين من هيئة الصحة بدبي. التحقق المباشر من تغطية التأمين عبر الواتساب على الرقم +971 54 548 8731.

2,800 AED
TAT: 3–4 Weeks
ISO 9001:2015 Certified

Comprehensive PGAP3 Genetic Profiling

The PGAP3 gene encodes a protein essential for glycosylphosphatidylinositol (GPI) anchor synthesis. Pathogenic variants cause Hyperphosphatasia with Intellectual Disability Syndrome Type 4 (HPMRS4), also known as Mabry syndrome, characterized by developmental delay, facial dysmorphism, seizures, and elevated serum alkaline phosphatase. Our NGS-based test sequences all coding exons and splice junctions of PGAP3 to detect single nucleotide variants, small insertions/deletions, and copy number changes, delivering a definitive molecular diagnosis for affected children and guiding family planning.

Feature	Our Test (PGAP3 NGS)	Closest Alternative
Technology	Next-Generation Sequencing (Illumina® platform) with full bioinformatic pipeline	Single-gene Sanger sequencing (limited to known hotspots)
Coverage	All coding exons, ±20 bp intron borders, CNV detection	Targeted mutation analysis only; misses novel variants
Turnaround	3–4 weeks	4–6 weeks
Clinical Interpretation	DHA-aligned report with ACMG 2026 classification	Often lacks geneticist review

Physician Insight & Safety Protocol

“A PGAP3 molecular diagnosis provides families with answers, ends the diagnostic odyssey, and enables precise recurrence risk counselling. However, a negative result does not rule out other GPI-anchor disorders; correlation with clinical and biochemical findings remains essential. Please never alter your child’s medication without direct medical advice.”

— Dr. Prabhakar Reddy, DHA License 61713011

⚠️ Medication Warning

Do not discontinue or adjust any prescribed therapies (antiepileptics, alkaline phosphatase modulators, etc.) based on this test result alone. Always consult your managing paediatrician or geneticist.

Exclusion Criteria & Emergency Red Flags

This test is not indicated for acute life‑threatening events; if the child is in respiratory distress, status epilepticus, or unresponsive, call 998 immediately.
Infants under 1 month of age require clinical clearance for home blood draw.
Patients with severe coagulopathy or platelet disorders: venipuncture must be performed under specialist supervision.
Red‑flag laboratory findings (e.g., extreme hyperphosphatasemia >10× upper limit, metabolic crisis) warrant urgent hospital admission before genetic testing.
Do not submit a sample if the patient has had a blood transfusion within the last 4 weeks—it may interfere with DNA integrity.

UAE Regulatory Compliance & Accreditation

Analysis performed in a facility licensed by the UAE Ministry of Health & Prevention (MOHAP) – Facility License 9834453.
All procedures conform to Federal Decree‑Law No. 41 of 2024 (Article 87), the UAE Child Data Safety (CDS) Law 2026 for minors, and the UAE Personal Data Protection Law (PDPL).
ISO 9001:2015 Quality Management System certified (Cert: INT/EGQ/2509DA/3139), ensuring validated NGS workflows and data security.

Frequently Asked Questions

1. What is the purpose of the PGAP3 genetic test?

The test identifies disease‑causing variants in the PGAP3 gene to confirm a clinical diagnosis of Hyperphosphatasia with Intellectual Disability Syndrome Type 4, enabling targeted management and accurate family counselling.

يهدف التحليل إلى كشف الطفرات المسببة للمرض في جين PGAP3 لتأكيد تشخيص متلازمة فرط الفوسفاتاز مع الإعاقة الذهنية من النوع الرابع، مما يتيح توجيه العلاج والإرشاد الوراثي الدقيق للعائلة.

2. How is the sample collected, and is home collection available?

A certified phlebotomist visits your home between 8 am and 11 pm to collect a small blood sample or an FTA card spot; the sample is transported in a temperature‑controlled chain to our ISO‑accredited lab.

يقوم أخصائي سحب دم مرخص بزيارة منزلكم بين 8 صباحاً و11 مساءً لجمع عينة دم بسيطة أو بقعة على بطاقة FTA، وتُنقل العينة ضمن سلسلة تبريد معتمدة إلى مختبرنا الحاصل على شهادة ISO.

3. Will my insurance cover this, and how quickly will I get results?

Most UAE insurers cover medically necessary genetic diagnostics; we verify your policy directly via WhatsApp (+971 54 548 8731) before the collection, and final report is ready in 3–4 weeks.

تغطي معظم شركات التأمين في الإمارات الفحوص الجينية الضرورية طبياً؛ نتحقق من وثيقتكم مباشرة عبر الواتساب (971 54 548 8731+) قبل جمع العينة، ويصدر التقرير النهائي خلال 3–4 أسابيع.

For Appointments & Insurance Verification

Call or WhatsApp +971 54 548 731 / +971 54 548 8731

Licensed home phlebotomy 8 am – 11 pm | Genetic counselling available in English and Arabic

دعم ثنائي اللغة متاح